Skip to content

Effect of preoperative oral Midazolam combined with intraoperative dexmedetomidine on postoperative quality of life in patients with breast cancer: a prospective, randomized, double-blind experimental study

Effect of preoperative oral Midazolam combined with intraoperative dexmedetomidine on postoperative quality of life in patients with breast cancer: a prospective, randomized, double-blind experimental study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093827
Enrollment
Unknown
Registered
2024-12-12
Start date
2024-04-17
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with breast cancer requiring general anesthesia

Interventions

M1:Preoperative oral Midazolam 10mg combined with intraoperative dexmedetomidine intravenous pumping
M2:Preoperative oral Midazolam 10mg
M3:Preoperative oral equivalent dose placebo

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria (1) Age 18-65 years old; (2) Deviation from ideal body weight = 25%; (3) American Association of Anesthesiologists ASA I-II; (4) The operation time is less than 2h for breast cancer patients; (5) No history of long-term use of analgesic, sedative and anti anxiety drugs in the past; (6) Informed consent, voluntarily participate in the experiment and sign an informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria (1) Patients with known Drug allergy to Midazolam or benzodiazepines, dexmedetomidine, acute closed eye glaucoma or open angle glaucoma without effective treatment; (2) Weight exceeds ideal weight by ± 25%; (3) Patients with any serious systemic organ disease (heart lung/kidney/liver), Nervous system disease (cerebral palsy, autism, etc.), or combined use of Anesthetic or other central nervous system inhibitors; (4) Patients who have taken any drugs that may interfere with the pharmacokinetics or pharmacodynamics of Midazolam, such as Antifungal, Macrolide antibiotics, Cimetidine, rifamycin or Calcium channel blockers; (5) Patients with communication barriers, cognitive impairment, and a history of mental illness; (6) Subjects deemed unsuitable by the researchers for participation in this study.

Design outcomes

Primary

MeasureTime frame
Postoperative 24 hour quality of life score QOR-15 scale;

Secondary

MeasureTime frame
heart rate;Blood oxygen saturation;blood pressure;Anxiety Visual Analog Scale;Hospital anxiety and depression scale,HADS;Ramsay Sedation Scale calmness level;Time for Ramsay score = 3;Pittsburgh sleep quality index, PSQI;visual analogue scale;QOR-15 Quality of Life Rating Scale;Anesthetic usage;Airway obstruction, coughing, mental disorders, nausea, vomiting, drowsiness, dizziness, skin itching, postoperative delirium, other adverse reactions, etc;

Countries

People's Republic of China

Contacts

Public ContactGuanghong Xu

The First Affiliated Hospital of Anhui Medical University

xuguanghong2004@163.com+86 138 5694 9535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026